首页> 外文期刊>Leukemia >Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL)
【24h】

Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL)

机译:通过PCR扩增弥漫性大B细胞淋巴瘤(DLBCL)中的免疫球蛋白基因重排进行分子分期的预后意义

获取原文
获取外文期刊封面目录资料

摘要

The prognostic value of the detection of peripheral blood (PB) and/or bone marrow (BM) involvement by polymerase chain reaction (PCR) amplification of rearranged immunoglobulin heavy chain (IgH) and immunoglobulin kappa light chain (Ig) genes was evaluated in 155 patients with diffuse large B-cell lymphomas (DLBCL). Immunoglobulin gene rearrangements (IgR) were detected in 35/155 (23%) patients. The presence of IgR in PB/BM was related to clinical stage (CS I–III vs CS IV; PPPP=0.042), and a significantly poorer overall survival (OAS) at 5 years (25 vs 66%; P<0.001). There was a significant difference in the estimated OAS at 5 years between patients with negative BM histology and negative PCR results (66%), patients with negative BM histology but positive IgR (37%), and patients with positive BM histology (12%). Our results indicate that molecular methods improve the accuracy of staging in patients with DLBCL and define a group of patients with normal bone marrow histology who have a significantly poorer OAS due to molecular detection of PB/BM involvement.
机译:在155中评估了通过聚合酶链反应(PCR)扩增重排的免疫球蛋白重链(IgH)和免疫球蛋白kappa轻链(Ig)基因检测外周血(PB)和/或骨髓(BM)的预后价值弥漫性大B细胞淋巴瘤(DLBCL)患者。在35/155(23%)患者中检测到免疫球蛋白基因重排(IgR)。 PB / BM中IgR的存在与临床阶段有关(CS I–III与CS IV; PPPP = 0.042),以及5年时的总生存期(OAS)明显较差(25 vs 66%; P <0.001)。 。 BM组织学阴性且PCR结果阴性的患者(66 %),BM组织学阴性但IgR阳性的患者(55%)的5年OAS估计值存在显着差异(12) %)。我们的结果表明,分子方法提高了DLBCL患者分期的准确性,并确定了一组正常的骨髓组织学患者,这些患者由于对PB / BM的分子检测而使OAS明显较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号